The Association Between Cervical Cancer Screening and Cancer Occurrence
The Association Between Cervical Cancer Screening Participation and Corresponding Results and Subsequent Cancer Occurrence and Death
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yun-Yuan Chen, PhD
- Phone Number: 23 +886 2 23910409
- Email: b87801006@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 10055
- Recruiting
- Taiwan Cervical Cancer Screening Task Force
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
The eligibility criteria in the proposal are specified in different part of analyses respectively, which are briefly listed below:
Part I:
- Include women covered by national screening program and they did not have previous cervical cancer history before the study initiate date.
Part II:
- Include women ever participated cervical cancer screening and exclude women with previous cervical cancer history before screening attending.
Part III:
- Include women without previous cervical cancer history before the follow-up initiation.
Part IV:
- Include women without previous cervical cancer history before the follow-up initiation.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Entire Taiwan women
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Chi-An Chen, MD, National Taiwan University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion
Primary Completion
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 200910043R
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
NCT03146039WithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III
-
NCT05093712WithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IIIC Cervical Cancer FIGO 2018
-
NCT07196033RecruitingStage IIA Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO 2018 | Stage IIIB Cervical Cancer FIGO 2018 | Stage IVA Cervical Cancer FIGO 2018 | Stage IB Cervical Cancer FIGO 2018
-
NCT04574635Active, not recruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018
-
NCT01019278WithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
NCT07266350Not yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
NCT07143292Not yet recruitingCervical Cancer Recurrent | Cervical Cancer Metastatic
-
NCT00559377CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer
-
NCT04723095RecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage IB Cervical Cancer AJCC v8 | Stage IB1 Cervical Cancer AJCC v8
-
NCT00054444CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer